Update and new approaches in the treatment of Castleman disease

References

• Case records of the Massachusetts general hospital weekly clinicopathological exercises: case 40011N Engl J Med19542501263013111435
   PubMedGoogle Scholar
• MunshiNMehraMvan de VeldeHDesaiAPotluriRVermeulenJUse of a claims database to characterize and estimate the incidence rate for Castleman diseaseLeuk Lymphoma20155651252126025120049
   PubMed Web of Science ®Google Scholar
• PowlesTStebbingJBazeosAThe role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s diseaseAnn Oncol200920477577919179554
   PubMed Web of Science ®Google Scholar
• TalatNSchulteKMCastleman’s disease: systematic analysis of 416 patients from the literatureOncologist20111691316132421765191
   PubMed Web of Science ®Google Scholar
• DispenzieriAArmitageJOLoeMJThe clinical spectrum of Castleman’s diseaseAm J Hematol20128711997100222791417
   PubMed Web of Science ®Google Scholar
• BowerMNewsom-DavisTNareshKClinical features and outcome in HIV-associated multicentric Castleman’s diseaseJ Clin Oncol201129182481248621555697
   PubMed Web of Science ®Google Scholar
• OksenhendlerEDuarteMSoulierJMulticentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patientsAIDS199610161678924253
   PubMed Web of Science ®Google Scholar
• RobinsonDReynoldsMCasperCClinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centresBr J Haematol20141651394824387011
   PubMed Web of Science ®Google Scholar
• DongYWangMNongLClinical and laboratory characterization of 114 cases of Castleman disease patients from a single centre: paraneoplastic pemphigus is an unfavourable prognostic factorBr J Haematol2015169683484225824806
   PubMed Web of Science ®Google Scholar
• DossierAMeigninVFieschiCBoutboulDOksenhendlerEGalicierLHuman herpesvirus 8-related Castleman disease in the absence of HIV infectionClin Infect Dis201356683384223223599
   PubMed Web of Science ®Google Scholar
• SoulierJGrolletLOksenhendlerEKaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s diseaseBlood1995864127612807632932
   PubMed Web of Science ®Google Scholar
• ZhaiSSimpsonDPolynesian variant of idiopathic multicentric Castleman diseaseBlood2013122215127
   Web of Science ®Google Scholar
• OksenhendlerECarcelainGAokiYHigh levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patientsBlood20009662069207310979949
   PubMed Web of Science ®Google Scholar
• FajgenbaumDCvan RheeFNabelCSHHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapyBlood2014123192924293324622327
   PubMed Web of Science ®Google Scholar
• ChangYCesarmanEPessinMSIdentification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcomaScience19942665192186518697997879
   PubMed Web of Science ®Google Scholar
• CesarmanEChangYMoorePSSaidJWKnowlesDMKaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomasN Engl J Med199533218118611917700311
   PubMed Web of Science ®Google Scholar
• NadorRGCesarmanEChadburnAPrimary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virusBlood19968826456568695812
   PubMed Web of Science ®Google Scholar
• BhutaniMPolizzottoMNUldrickTSYarchoanRKaposi sarcoma-associated herpesvirus-associated malignancies: epidemiology, pathogenesis, and advances in treatmentSemin Oncol201542222324625843728
   PubMed Web of Science ®Google Scholar
• FloreORafiiSElySO’LearyJJHyjekEMCesarmanETransformation of primary human endothelial cells by Kaposi’s sarcoma-associated herpesvirusNature199839466935885929707121
   PubMed Web of Science ®Google Scholar
• HassmanLMEllisonTJKedesDHKSHV infects a subset of human tonsillar B cells, driving proliferation and plasmablast differentiationJ Clin Invest2011121275276821245574
   PubMed Web of Science ®Google Scholar
• GanemDKSHV infection and the pathogenesis of Kaposi’s sarcomaAnnu Rev Pathol2006127329618039116
   PubMed Web of Science ®Google Scholar
• YoshizakiKMatsudaTNishimotoNPathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s diseaseBlood1989744136013672788466
   PubMed Web of Science ®Google Scholar
• BrandtSJBodineDMDunbarCENienhuisAWDysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in miceJ Clin Invest19908625925992384605
   PubMed Web of Science ®Google Scholar
• SuthausJStuhlmann-LaeiszCTompkinsVSHHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in miceBlood2012119225173518122490805
   PubMed Web of Science ®Google Scholar
• BurgerRNeipelFFleckensteinBHuman herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cellsBlood1998916185818639490667
   PubMed Web of Science ®Google Scholar
• SchwarzMMurphyPMKaposi’s sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinantJ Immunol2001167150551311418689
   PubMed Web of Science ®Google Scholar
• AnJLichtensteinAKBrentGRettigMBThe Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response elementBlood200299264965411781250
   PubMed Web of Science ®Google Scholar
• MoriYNishimotoNOhnoMHuman herpesvirus 8-encoded interleukin-6 homologue (viral IL-6) induces endogenous human IL-6 secretionJ Med Virol200061333233510861641
   PubMed Web of Science ®Google Scholar
• AokiYJaffeESChangYAngiogenesis and hematopoiesis induced by Kaposi’s sarcoma-associated herpesvirus-encoded interleukin-6Blood199993124034404310361100
   PubMed Web of Science ®Google Scholar
• PolizzottoMNUldrickTSWangVHuman and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman diseaseBlood2013122264189419824174627
   PubMed Web of Science ®Google Scholar
• KawabataHTomosugiNKandaJTanakaYYoshizakiKUchiyamaTAnti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman’s diseaseHaematologica200792685785817550864
   PubMed Web of Science ®Google Scholar
• RossiJFLuZYJourdanMKleinBInterleukin-6 as a therapeutic targetClin Cancer Res20152161248125725589616
   PubMed Web of Science ®Google Scholar
• TalatNBelgaumkarAPSchulteKMSurgery in Castleman’s disease: a systematic review of 404 published casesAnn Surg2012255467768422367441
   PubMed Web of Science ®Google Scholar
• MarshJHColbournDSDonovanVStaszewskiHSystemic Castleman’s disease in association with Evan’s syndrome and vitiligoMed Pediatr Oncol19901821691722304424
   PubMedGoogle Scholar
• MariettaMPozziSLuppiMAcquired haemophilia in HIV negative, HHV-8 positive multicentric Castleman’s disease: a case reportEur J Haematol200370318118212605662
   PubMed Web of Science ®Google Scholar
• DispenzieriAKyleRALacyMQPOEMS syndrome: definitions and long-term outcomeBlood200310172496250612456500
   PubMed Web of Science ®Google Scholar
• KawabataHTakaiKKojimaMCastleman–Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012)J Clin Exp Hematop2013531576123801135
   PubMedGoogle Scholar
• D’SouzaAHaymanSRBuadiFThe utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndromeBlood2011118174663466521881050
   PubMed Web of Science ®Google Scholar
• RobinsonHPrinceHMRamdaveSSeymourJFElliottPHicksRPreliminary experience of 18F-fluorodeoxyglucose positron emission tomography in Castleman’s diseaseLeuk Lymphoma200647122664266617169817
   PubMed Web of Science ®Google Scholar
• BarkerRKazmiFStebbingJFDG-PET/CT imaging in the management of HIV-associated multicentric Castleman’s diseaseEur J Nucl Med Mol Imaging200936464865219050873
   PubMed Web of Science ®Google Scholar
• PolizzottoMNMilloCUldrickTS18F-fluorodeoxyglucose positron emission tomography in kaposi sarcoma herpesvirus-associated multicentric Castleman disease: correlation with activity, severity, inflammatory and virologic parametersJ Infect Dis201521281250126025828248
   PubMed Web of Science ®Google Scholar
• CastlemanBIversonLMenendezVPLocalized mediastinal lymphnode hyperplasia resembling thymomaCancer19569482283013356266
   PubMed Web of Science ®Google Scholar
• KellerARHochholzerLCastlemanBHyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locationsCancer19722936706834551306
   PubMed Web of Science ®Google Scholar
• DupinNDissTLKellamPHHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphomaBlood20009541406141210666218
   PubMed Web of Science ®Google Scholar
• CroninDMWarnkeRACastleman disease: an update on classification and the spectrum of associated lesionsAdv Anat Pathol200916423624619546611
   PubMed Web of Science ®Google Scholar
• BanderaBAinsworthCShikleJRupardERoachMTreatment of unicentric Castleman disease with neoadjuvant rituximabChest201013851239124121051400
   PubMed Web of Science ®Google Scholar
• FitzpatrickPJBrownTCAngiofollicular lymph node hyperplasiaCan Med Assoc J19689925125912625700853
   PubMed Web of Science ®Google Scholar
• NordstromDGTewfikHHLatouretteHBPlasma cell giant lymph node hyperplasia responding to radiation therapyAJR Am J Roentgenol19781301169171413407
   PubMed Web of Science ®Google Scholar
• StokesSHGriffithRCThomasPRAngiofollicular lymph node hyperplasia (Castleman’s disease) associated with vertebral destructionCancer19855648768794016679
   PubMed Web of Science ®Google Scholar
• WeisenburgerDDDeGowinRLGibsonPArmitageJORemission of giant lymph node hyperplasia with anemia after radiotherapyCancer1979442457462476562
   PubMed Web of Science ®Google Scholar
• MasseyGVKornsteinMJWahlDHuangXLMcCradyCWCarchmanRAAngiofollicular lymph node hyperplasia (Castleman’s disease) in an adolescent female. Clinical and immunologic findingsCancer1991686136513721873789
   PubMed Web of Science ®Google Scholar
• VeldhuisGJvan der LeestAHde WolfJTde VriesEGVellengaEA case of localized Castleman’s disease with systemic involvement: treatment and pathogenetic aspectsAnn Hematol199673147508695726
   PubMed Web of Science ®Google Scholar
• BowneWBLewisJJFilippaDAThe management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literatureCancer199985370671710091744
   PubMed Web of Science ®Google Scholar
• ChronowskiGMHaCSWilderRBCabanillasFManningJCoxJDTreatment of unicentric and multicentric Castleman disease and the role of radiotherapyCancer200192367067611505414
   PubMed Web of Science ®Google Scholar
• NeuhofDDebusJOutcome and late complications of radiotherapy in patients with unicentric Castleman diseaseActa Oncol20064581126113117118850
   PubMed Web of Science ®Google Scholar
• LiYMLiuPHZhangYHRadiotherapy of unicentric mediastinal Castleman’s diseaseChin J Cancer201130535135621527068
   PubMedGoogle Scholar
• MatthiesenCRamgopolRSeaveyJAhmadSHermanTIntensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literatureRadiol Oncol201246326527023077466
   PubMed Web of Science ®Google Scholar
• MirandaFAFariaVHArrudaGVSilvaLGRadiation therapy in the treatment of unicentric Castleman’s diseaseJ Bras Pneumol201339111611823503497
   PubMed Web of Science ®Google Scholar
• ScottDCabralLHarringtonWJTreatment of HIV-associated multicentric Castleman’s disease with oral etoposideAm J Hematol200166214815011421297
   PubMed Web of Science ®Google Scholar
• BordeleauLBredesonCMarkmanS2-Chloro-deoxyadenosine therapy for giant lymph node hyperplasiaBr J Haematol19959136686708555073
   PubMed Web of Science ®Google Scholar
• ColleoniGWDuarteLCKerbauyFR2-Chloro-deoxyadenosine induces durable complete remission in Castleman’s disease but may accelerate its transformation to non-Hodgkin’s lymphomaActa Oncol200342778478714690166
   PubMed Web of Science ®Google Scholar
• HerradaJCabanillasFRiceLManningJPughWThe clinical behavior of localized and multicentric Castleman diseaseAnn Intern Med199812886576629537940
   PubMed Web of Science ®Google Scholar
• ZhuSHYuYHZhangYSunJJHanDLLiJClinical features and outcome of patients with HIV-negative multicentric Castleman’s disease treated with combination chemotherapy: a report on 10 patientsMed Oncol201330149223400962
   PubMed Web of Science ®Google Scholar
• GérardLBéreznéAGalicierLProspective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB TrialJ Clin Oncol200725223350335617664482
   PubMed Web of Science ®Google Scholar
• BowerMPowlesTWilliamsSBrief communication: rituximab in HIV-associated multicentric Castleman diseaseAnn Intern Med20071471283683918087054
   PubMed Web of Science ®Google Scholar
• IdeMKawachiYIzumiYKasagiKOginoTLong-term remission in HIV-negative patients with multicentric Castleman’s disease using rituximabEur J Haematol200676211912316405432
   PubMed Web of Science ®Google Scholar
• UldrickTSPolizzottoMNAlemanKRituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman diseaseBlood2014124243544355225331113
   PubMed Web of Science ®Google Scholar
• HoffmannCSchmidHMüllerMImproved outcome with rituximab in patients with HIV-associated multicentric Castleman diseaseBlood2011118133499350321778341
   PubMed Web of Science ®Google Scholar
• GérardLMichotJMBurcheriSRituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman diseaseBlood2012119102228223322223822
   PubMed Web of Science ®Google Scholar
• UldrickTSPolizzottoMNAlemanKHigh-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapyBlood2011117266977698621487108
   PubMed Web of Science ®Google Scholar
• CasperCNicholsWGHuangMLCoreyLWaldARemission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatmentBlood200410351632163414615380
   PubMed Web of Science ®Google Scholar
• BerezneAAgbalikaFOksenhendlerEFailure of cidofovir in HIV-associated multicentric Castleman diseaseBlood20041031143684369 author reply 436915155471
   PubMed Web of Science ®Google Scholar
• TamayoMGonzalezCMajadoMJCandelRRamosJLong-term complete remission after interferon treatment in a case of multicentric Castelman’s diseaseAm J Hematol19954943593607639289
   PubMed Web of Science ®Google Scholar
• KumariPSchechterGPSainiNBenatorDASuccessful treatment of human immunodeficiency virus-related Castleman’s disease with interferon-alphaClin Infect Dis200031260260410987728
   PubMed Web of Science ®Google Scholar
• AndrèsEMaloiselFInterferon-alpha as first-line therapy for treatment of multicentric Castleman’s diseaseAnn Oncol200011121613161411205472
   PubMed Web of Science ®Google Scholar
• LeeFCMerchantSHAlleviation of systemic manifestations of multicentric Castleman’s disease by thalidomideAm J Hematol2003731485312701121
   PubMed Web of Science ®Google Scholar
• JungCPEmmerichBGoebelFDBognerJRSuccessful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomideAm J Hematol200475317617714978701
   PubMed Web of Science ®Google Scholar
• StaryGKohrgruberNHernethAMGaigerAStinglGRiegerAComplete regression of HIV-associated multicentric Castleman disease treated with rituximab and thalidomideAIDS200822101232123418525273
   PubMed Web of Science ®Google Scholar
• RamasamyKGandhiSTenant-FlowersMRituximab and thalidomide combination therapy for Castleman diseaseBr J Haematol2012158342142322583139
   PubMed Web of Science ®Google Scholar
• SzturzPAdamZChovancováJLenalidomide: a new treatment option for Castleman diseaseLeuk Lymphoma201253102089209121902577
   PubMed Web of Science ®Google Scholar
• YuanZGDunXYLiYHHouJTreatment of multicentric Castleman’s disease accompanying multiple myeloma with bortezomib: a case reportJ Hematol Oncol200921919400935
   PubMed Web of Science ®Google Scholar
• SobasMAAlonso VenceNDiaz AriasJBendaña LopezAFraga RodriguezMBello LopezJLEfficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant)Ann Hematol201089221721919636554
   PubMed Web of Science ®Google Scholar
• SbengheMMBesaEMahipalADulau FloreaABrayPCaroJHHV-8-associated multicentric Castleman’s disease in HIV-negative patient: a novel therapy for an orphan diseaseOncologist2012171145146 author reply 147–14822286773
   PubMed Web of Science ®Google Scholar
• KhanAASirajFBhargavaMAggarwalSSuccessful treatment of multicentric Castleman’s disease accompanying myeloma with bortezomibBMJ Case Rep20122012 pii:bcr2012007646
   Google Scholar
• LinQFangBHuangHEfficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman’s diseaseBlood Cancer J20155e29825794134
   PubMed Web of Science ®Google Scholar
• RepettoLJaiprakashMPSelbyPJGustersonBAWilliamsHJMcElwainTJAggressive angiofollicular lymph node hyperplasia (Castleman’s disease) treated with high dose melphalan and autologous bone marrow transplantationHematol Oncol1986432132173533746
   PubMed Web of Science ®Google Scholar
• GantiAKPipinosICulceaEArmitageJOTarantoloSSuccessful hematopoietic stem-cell transplantation in multicentric Castleman disease complicated by POEMS syndromeAm J Hematol200579320621015981232
   PubMed Web of Science ®Google Scholar
• TalYHaberGCohenMJAutologous stem cell transplantation in a rare multicentric Castleman disease of the plasma cell variantInt J Hematol201193567768021437636
   PubMed Web of Science ®Google Scholar
• KurzrockRVoorheesPMCasperCA phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseClin Cancer Res201319133659367023659971
   PubMed Web of Science ®Google Scholar
• van RheeFWongRSMunshiNSiltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trialLancet Oncol201415996697425042199
   PubMed Web of Science ®Google Scholar
• van RheeFCasperCVoorheesPMA Phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman diseaseOncotarget2015630304083041926327301
   PubMed Web of Science ®Google Scholar
• NishimotoNKanakuraYAozasaKHumanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman diseaseBlood200510682627263215998837
   PubMed Web of Science ®Google Scholar
• MatsuyamaMSuzukiTTsuboiHAnti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman’s diseaseIntern Med2007461177177417541233
   PubMed Web of Science ®Google Scholar
• GaleottiCBoucheronAGuillaumeSKoné-PautISustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibodyMol Cancer Ther20121181623162622638145
   PubMed Web of Science ®Google Scholar
• KandaJKawabataHYamajiYReversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibodyInt J Hematol200785320721117483056
   PubMed Web of Science ®Google Scholar
• YuzurihaASaitohTKoisoHSuccessful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapyActa Haematol2011126314715021757886
   PubMed Web of Science ®Google Scholar
• OshitariTKajitaFTobeARefractory uveitis in patient with castleman disease successfully treated with tocilizumabCase Rep Ophthalmol Med2012201296818023198204
   PubMedGoogle Scholar
• ShirakawaKEgashiraTIedaMMultidisciplinary approach to the treatment of cardiac AA amyloidosis and aortic stenosis due to Castleman’s disease: a hybrid therapy with tocilizumab and aortic valve replacementInt J Cardiol20141732e9e1124681024
   PubMed Web of Science ®Google Scholar
• NagaoANakazawaSHanabusaHShort-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two casesJ Hematol Oncol201471024438824
   PubMed Web of Science ®Google Scholar
• GaleottiCTranTAFranchi-AbellaSFabreMParienteDKoné-PautIIL-1RA agonist (anakinra) in the treatment of multifocal castleman disease: case reportJ Pediatr Hematol Oncol2008301292092419131781
   PubMed Web of Science ®Google Scholar
• El-OstaHJankuFKurzrockRSuccessful treatment of Castleman’s disease with interleukin-1 receptor antagonist (Anakinra)Mol Cancer Ther2010961485148820501803
   PubMed Web of Science ®Google Scholar
• ZietzCBognerJRGoebelFDLöhrsUAn unusual cluster of cases of Castleman’s disease during highly active antiretroviral therapy for AIDSN Engl J Med1999340241923192410375310
   PubMed Web of Science ®Google Scholar
• NewmanSKJayanthanRKMitchellGWTaking control of Castleman disease: leveraging precision medicine technologies to accelerate rare disease researchYale J Biol Med201588438338826604862
   PubMedGoogle Scholar